Asembia Unveils Pur-IQ™: A Revolutionary Data Quality Solution for Specialty Pharmacies
New Platform Enhances Data Accuracy, Reduces Delays, and Optimizes
Specialty Pharmacy Operations
The innovative solution provides real-time notifications to designated specialty pharmacy users, alerting them of data errors and missing fields. With an intuitive interface, Pur-IQ enables quick and easy corrections, ensuring accurate data submission and minimizing disruptions.
Key Benefits of Pur-IQ:
- Accelerates timelines – Reduces delays by identifying and resolving data discrepancies promptly.
- Increases participation – Encourages broader engagement in data programs with seamless implementation.
- Minimizes rework and phone calls – Reduces inefficiencies by automating error detection and resolution.
- Bridges IT, data, business, and operations – Connects critical teams to enhance workflow and collaboration.
"For over a decade, Asembia has been at the forefront of specialty pharmacy innovation, committed to reducing friction and empowering our partners," said
As specialty pharmacies continue to navigate an evolving healthcare landscape, Pur-IQ stands as a transformative solution that enhances data integrity and operational efficiency.
For more information about Pur-IQ and Asembia's suite of specialty pharmacy solutions, contact us at: [email protected] or use the following link: https://qrcodes.pro/idw6D2
About Asembia
Asembia is a leading healthcare solutions provider, dedicated to advancing specialty pharmacy services through technology, data-driven solutions, and collaborative partnerships. With a mission to optimize patient access and outcomes, Asembia continues to drive innovation across the healthcare ecosystem.
Media Contact:
VP Marketing
Asembia
P: 973-564-8004
E: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/asembia-unveils-pur-iq-a-revolutionary-data-quality-solution-for-specialty-pharmacies-302434870.html
SOURCE Asembia
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IonOpticks launches Aurora Series® 5 and new CoreJet™ emitter technology, advancing robust nano-LC for routine proteomics research.
- Everlight Wins 2026 Madison People's Choice Award
- Phase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung Cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share